One day after AIDS activists petitioned the U.S. Patent and Trademark Office last week to reject a request by Gilead Sciences (GILD) for a patent extension on an HIV drug, a senior legal adviser at the federal agency tweeted contentious remarks about their right to take such a step. She also challenged a key point in their filing.

Now, the activists have filed yet another petition with the USPTO and accused the legal adviser of making inappropriate remarks and displaying favoritism toward Gilead. And the activists, known as the PrEP4All Collaboration, have also asked the USPTO to reassign the adviser — a 14-year-employee named Mary Till — while their petition remains active.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy